

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CHINA HEALTH GROUP INC.**

(中國醫療集團有限公司)

(Carrying on business in Hong Kong as “萬全醫療集團”)

(Formerly known as “Venturepharm Laboratories Limited”)

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 08225)

**Voluntary Announcement of China Health Group INC. Business Update**

On 6 February 2023, China Health Group INC. (the group) signed a cooperation agreement with Xinjiang Huachun Bio-Pharmaceutical Co. The management of the Company believes that this will have a positive impact on the Group's future operations and results.

In the post-epidemic era, the prevalence of mental illness is on a significant rise. According to a set of data provided by Lu Lin, an academician from the Chinese Academy of Sciences, nearly 70 million new depression patients have been added worldwide in the three years since the outbreak of the new crown epidemic. The impact of the epidemic on the mental health of the entire population will last at least 10 to 20 years. The Group believes that continued collaboration on such projects will further strengthen the Group's leading position in this field and bring substantial benefits to our shareholders.

China Health Group Inc. is a leading digital healthcare service provider in the areas of new drug development innovation, research-based specialty clinics and research-based product promotion, driven by real-world clinical research and medical big data. The Group focuses on major disease areas such as brain science and allergic reactions, and has built up five major specialty brands: Baimin, Xixin, Xien, Yuejie and Rare Diseases.

The management of the company believes that the growth of the company's medical services, especially in the field of psychiatric neurology after the epidemic, will bring sustainable development to the business. Therefore, this announcement is made. Due to the great uncertainty in the market, professionals are advised to exercise caution in their investment.

By order of the Board  
**China Health Group Inc.**  
**William Xia GUO**  
*Chairman*

Hong Kong, 28 February, 2023

*As at the date of this supplemental announcement, the Board comprises two executive Directors, being Mr. GUO Xia and Dr. SONG Xuemei; one non-executive Director, being Ms. ZHANG Li; and three independent non-executive Directors, being Mr. QIU Rui, Dr. NI Binhui and Mr. ZHEN Ling.*

*This announcement, for which the directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the GEM website with the domain name of [www.hkgem.com](http://www.hkgem.com) on the “Latest Company Announcements” page for at least 7 days from the date of its posting and on the Company’s website at [www.chgi.net](http://www.chgi.net).*